Sponsored by TriVascular, Inc.
evt | Article | September 2014 Supplement
Sponsored by Boston Scientific Corporation
evt | Article | September 2017 Europe Supplement
Sponsored by Cook Medical
evt | Article | March 2013 Supplement
Sponsored by Intact Vascular®, Inc.
evt | Article | June 2013
evt | Article | March 2019
EVAR in 3D: The Leipzig Experience
Exploring the role of three-dimensional printing in preprocedural planning and custom fenestration in physician-modified grafts to treat acute, complex abdominal and thoracoabdominal aortic pathologies.
By Daniela Branzan, MD; Andrej Schmidt, MD, PhD; Dirk Winkler, MD, PhD; Dierk Scheinert, MD, PhD; and Ronny Grunert, PhD
evt | Article | September 2018
Bioresorbable Stent Technology for Femoropopliteal Disease Treatment: Where Do We Stand?
Appraising the current literature on bioresorbable technology use in the SFA, what can be learned from the coronary experience, and the future of bioresorbable stents in this anatomy.
By Sabine Steiner, MD; Andrej Schmidt, MD; and Dierk Scheinert, MD
evt | Article | February 2015
Industry Consolidation's Potential Effects on Meetings and Physician Education
Endovascular Today asked for perspectives from leading conference organizers by posing the question, “To what degree are you concerned about how industry consolidation could affect support for vascular meetings and physician education?”
With Gary M. Ansel, MD; Barry T. Katzen, MD; Dierk Scheinert, MD; Roger M. Greenhalgh, MD; Sean P. Lyden, MD; and Frank J. Veith, MD
evt | News | October 9, 2013
evt | News | September 20, 2016
evt | News | March 2, 2015
BIOLUX P-I Study of Biotronik's Passeo-18 Lux DCB Published
March 3, 2014—Biotronik announced that Dierk Scheinert, MD, et al published 12-month results from the BIOLUX P-I clinical study in the Journal of Endovascular Therapy (2015;22:14–21). BIOLUX P-I was a first-in-human evaluation of the safety and efficacy of the company’s Passeo-18 Lux drug-coated balloon (DCB) in treating de novo and restenotic femoropopliteal lesions.